nach oben

Erschienen in:

01.01.2007 | Original Article

Modulatory Effect of Nitric Oxide on Mast Cells During Induction of Dextran Sulfate Sodium Colitis

verfasst von: Sebastian Videla, Jaime Vilaseca, Carlos Medina, Marisabel Mourelle, Francisco Guarner, Aantonio Salas, Juan-Ramon Malagelada

Erschienen in: Digestive Diseases and Sciences | Ausgabe 1/2007

Einloggen, um Zugang zu erhalten

Abstract

Nitric oxide (NO) is implicated in the pathophysiology of intestinal inflammation. Intestinal mast cells may amplify inflammatory response and mucosal injury in inflammatory bowel disease. Our aim was to examine the role of NO and intestinal mast cells by investigating the effects of NO synthase (NOS) inhibitors and a mast cell stabilizer during induction of dextran sulfate sodium (DSS) colitis. Colitis was induced by 4% DSS in drinking water, in rats pretreated with L-NAME or aminoguanidine. In another set of experiments, we investigated the effect of ketotifen in this setting. Inhibition of NO by L-NAME worsened DSS-induced inflammation, however, aminoguanidine had no effect. On the other hand, ketotifen abolished the deleterious effects of L-NAME on colonic inflammation, suggesting that hyperactivation of mast cells by NOS inhibition amplifies mucosal injury induced by DSS. Our results suggest that constitutive isoforms of NOS prevent mast cell activation.

De Belder AJ, Radomski MW (1994) Nitric oxide in the clinical arena. J Hypertens 12(6):617–624PubMedCrossRef

Knowles RG (1996) Nitric oxide synthases. Biochem Soc Trans 24:875–878PubMed

Cross RK, Wilson KT (2003) Nitric oxide in inflammatory bowel disease. Inflamm Bowel Dis 9:179–189PubMedCrossRef

Lundberg JO, Hellstrom PM, Lundberg JM, Alving K (1994) Greatly increased luminal nitric oxide in ulcerative colitis. Lancet 344:1344–1350CrossRef

Binion DG, Fu S, Ramanujam KS, Chai YC, Dweik RA, Drazba JA, Wade JG, Ziats NP, Erzurum SC, Wilson KT (1998) INOS expression in human intestinal microvascular endothelial cells inhibits leukocyte adhesion. Am J Physiol 275:G592–G603PubMed

Vento P, Kiviluoto T, Jarvinen HJ, Soinila S (2001) Changes in distribution of three isoforms of nitric oxide synthase in ulcerative colitis. Scand J Gastroenterol 36:180–189PubMedCrossRef

Gurish MF, Austen KF (2001) The diverse roles of mast cells. J Exp Med 194:F1–F5PubMedCrossRef

Wedemeyer J, Tsai M, Galli SJ (2000) Roles of mast cells and basophils in innate and acquired immunity. Curr Opin Immunol 12:624–631PubMedCrossRef

Brightling CE, Bradding P, Pavord ID, Wardlaw AJ (2003) New insights into the role of the mast cell in asthma. Clin Exp Allergy 33:550–556PubMedCrossRef

10.

Benoist C, Mathis D (2002) Mast cells in autoimmune disease. Nature 420:875–878PubMedCrossRef

11.

He SH (2004) Key role of mast cells and their major secretory products in inflammatory bowel disease. World J Gastroenterol 10:309–318PubMed

12.

Winterkamp S, Weidenhiller M, Otte P, Stolper J, Schwab D, Hahn EG, Raithel M (2002) Urinary excretion of N-methylhistamine as a marker of disease activity in inflammatory bowel disease. Am J Gastroenterol 97:3071–3077PubMedCrossRef

13.

Gelbmann CM, Mestermann S, Gross V, Kollinger M, Scholmerich J, Falk W (1999) Strictures in Crohn’s disease are characterised by an accumulation of mast cells colocalised with laminin but not with fibronectin or vitronectin. Gut 45:210–217PubMedCrossRef

14.

Bischoff SC, Lorentz A, Schwengberg S, Weier G, Raab R, Manns MP (1999) Mast cells are an important cellular source of tumour necrosis factor alpha in human intestinal tissue. Gut 44:643–652PubMedCrossRef

15.

Kanwar S, Wallace JL, Befus D, Kubes P (1994) Nitric oxide synthesis inhibition increases epithelial permeability via mast cells. Am J Physiol 266:G222–G229PubMed

16.

Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R (1990) A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 98:694–702PubMed

17.

Mourelle M, Casellas F, Guarner F, Salas A, Riveros-Moreno V, Moncada S, Malagelada JR (1995) Induction of nitric oxide synthase in colonic smooth muscle from patients with toxic megacolon. Gastroenterology 109:1497–1502PubMedCrossRef

18.

Mourelle M, Vilaseca J, Guarner F, Salas A, Malagelada JR (1996) Toxic dilatation of colon in a rat model of colitis is linked to an inducible form of nitric oxide synthase. Am J Physiol 270:G425–G430PubMed

19.

Vilaseca J, Salas A, Guarner F, Rodriguez R, Malagelada JR (1990) Participation of thromboxane and other eicosanoids synthesis in the course of experimental colitis. Gastroenterology 98:269–277PubMed

20.

Schierwagen C, Bylund-Fellenius AC, Lundberg C (1990) Improved method for quantification of tissue PMN accumulation measured by myeloperoxidase activity. J Pharmacol 23:179–186

21.

Cooper HS, Murthy SN, Shah RS, Sedergran DJ (1993) Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 69:238–249PubMed

22.

Vallance BA, Dijkstra G, Qiu B, van der Waaij LA, van Goor H, Jansen PL, Mashimo H, Collins SM (2004) Relative contributions of NOS isoforms during experimental colitis: endothelial-derived NOS mantains mucosal integrity. Am J Physiol Gastrointest Liver Physiol 287:G865–G874PubMedCrossRef

23.

Yamada T, Sartor RB, Mashall S, Specian RD, Grisham MB (1993) Mucosal injury and inflammation. I. A model of chronic granumolatosis colitis in rats. Gastroenterology 104:759–771PubMed

24.

Grisham MB, Specian RD, Zimmerman TE (1994) Effects of nitric oxide synthase inhibition on the pathophysiology observed in a model of chronic granulomatous colitis. J Pharmacol Exp Ther 271:1114–1121PubMed

25.

Pfeiffer CJ, Qiu BS (1995) Effects of chronic nitric oxide synthase inhibition on TNB-induced colitis. J Pharm Pharmacol 47:827–832PubMed

26.

Colon AL, Menchen LA, Hurtado O, De Cristobal J, Lizasoain I, Leza JC, Lorenzo P, Moro MA (2001) Implication of TNF-alpha convertase (TACE/ADAM17) in inducible nitric oxide synthase expression and inflammation in an experimental model of colitis. Cytokine 16:220–226PubMedCrossRef

27.

Kankuri E, Vaali K, Knowles RG, Lahde M, Korpela R, Vapaatalo H, Moilanen E (2001) Suppression of acute experimental colitis by a highly selective inducible nitric-oxide synthase inhibitor, N-[3-(aminomethyl)benzyl]acetamidine. J Pharmacol Exp Ther 298:1128–1132PubMed

28.

Hogoboam CM, Jacobson K, Collins SM, Blennerhassett MG (1995) The selective beneficial effects of nitric oxide inhibition in experimental colitis. Am J Physiol Gastrointest Liver Physiol 268:G673–G684

29.

Sasaki M, Bharwani S, Jordan P, Elrod JW, Grisham MB, Jackson TH, Lefer DJ, Alexander JS (2003) Increased disease activity in eNOS-deficient mice in experimental colitis. Free Radic Biol Med 35:1679–1687PubMedCrossRef

30.

Beck PL, Xavier R, Wong J, Ezedi I, Mashimo H, Mizoguchi A, Mizoguchi E, Bhan AK, Podolsky DK (2004) Paradoxical roles of different nitric oxide synthase isoforms in colonic injury. Am J Physiol Gastrointest Liver Physiol 286:G137–G147PubMedCrossRef

31.

Coleman JW (2002) Nitric oxide: a regulator of mast cell activation and mast cell-mediated inflammation. Clin Exp Immunol 129:4–10PubMedCrossRef

32.

Konaka A, Nishijima M, Tanaka A, Kunikata T, Kato S, Takeuchi K (1999) Nitric oxide, superoxide radicals and mast cells in pathogenesis of indomethacin-induced small intestinal lesions in rats. J Physiol Pharmacol 50:25–38PubMed

33.

Fukumoto Y, Kasai H, Takahashi H, Sugiyama H, Hase N, Kaneko H, Hamamura I, Aoki Y, Ota M, Kobayashi T, Katsuura Y, Kamimura T, Komoriya K (2002) The role of mast cells in the development of 2, 4, 6-trinitrobenzene sulfonic acid-induced colitis in rats. Scand J Gastroenterol 37:555–560PubMedCrossRef

Titel: Modulatory Effect of Nitric Oxide on Mast Cells During Induction of Dextran Sulfate Sodium Colitis
verfasst von: Sebastian Videla
Jaime Vilaseca
Carlos Medina
Marisabel Mourelle
Francisco Guarner
Aantonio Salas
Juan-Ramon Malagelada
Publikationsdatum: 01.01.2007
Verlag: Springer US
Erschienen in: Digestive Diseases and Sciences / Ausgabe 1/2007
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-006-9409-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Modulatory Effect of Nitric Oxide on Mast Cells During Induction of Dextran Sulfate Sodium Colitis

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2007

Amifostine (Wr-2721) Prevents Indomethacin-Induced Gastric Damage in Rats: Role of Non-Protein Sulfhydryl Groups and Leukocyte Adherence

Phenytoin-Potentiated Hepatotoxicity Following Acetaminophen Overdose? A Closer Look

Antioxidant Effects of Metronidazole in Colonic Tissue

Mesenteric Venous Thrombosis Following Laparoscopic Antireflux Surgery

Does Adding Misoprostol to Standard Intravenous Proton Pump Inhibitor Protocol Improve the Outcome of Aspirin/NSAID-Induced Upper Gastrointestinal Bleeding?

The Effect of Oral α-Galactosidase on Intestinal Gas Production and Gas-Related Symptoms

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin